Anidulafungin to replace caspofungin in the treatment of fungal infections in cancer patients.

Trial Profile

Anidulafungin to replace caspofungin in the treatment of fungal infections in cancer patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2015

At a glance

  • Drugs Anidulafungin (Primary)
  • Indications Candidaemia; Candidiasis; Systemic mycoses
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
    • 07 Sep 2015 New trial record
    • 25 Aug 2015 Results published in the Journal of Antimicrobial Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top